Superdisintegrants Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 599.20 Mn

Forecast Year, 2035

USD 1,025.45 Mn

CAGR, 2026 - 2035

5.52%

Report Coverage

Global

What is Superdisintegrants Market Size in 2026?

The global superdisintegrants market size was calculated at USD 599.20 million in 2025 and is predicted to increase from USD 632.27 million in 2026 to approximately USD 1,025.45 million by 2035, expanding at a CAGR of 5.52% from 2026 to 2035. The market growth is attributed to the rising demand for rapid disintegrating oral dosage forms and the increasing adoption of advanced excipient technologies.

Key Takeaways

• North America dominated the global market in 2025.
• Asia-Pacific is expected to grow at the fastest CAGR between 2026 and 2035.
• By product, the crospovidone segment contributed the highest market share in 2025.
• By product, the ion exchange resin segment is expected to grow at a strong CAGR between 2026 and 2035.
• By form, the tablets and capsules segment held a major market share in 2025.
• By form, the mouth-dissolving films (MDFs) segment is expected to expand at a rapid CAGR from 2026 to 2035.

Which Factors Drive the Superdisintegrants Industry?

The superdisintegrants market is being driven by the rapid global increase in demand for oral solid dosage forms. Tablets and capsules are still the most used drug forms, with 82.5% of immediate-release oral products being solid dosage forms, 64.5% in the form of tablets, and 22.7% in the form of capsules, according to the 2023 NIH report. Superdisintegrants are substances added to tablets and capsules to allow them to disintegrate rapidly in the gastrointestinal fluids. This enhances the dissolution and bioavailability of drugs. Furthermore, the oral medication demand remains a key market growth for the superdisintegrants sector.

Impact of Artificial Intelligence on the Superdisintegrants Market

Artificial Intelligence is reshaping how pharmaceutical formulation scientists design and optimize excipient systems. This enables rapid prediction of ideal excipient combinations and reduces trial-and-error experimentation. Machine learning and neural networks are types of AI models that predict important parameters of the formulation, including solubility, dissolution behavior, and excipient-API compatibility, accelerating dosage form design with fewer laboratory experiments than traditional dosage form design methods. Moreover, researchers are now adding AI to high-throughput experimentation systems to enable automated labs to screen hundreds of formulation permutations per day and update models with real-time feedback.

Superdisintegrants Market Trends

• Personalized Medicine Formulation Customization
  Pharmaceutical companies are shifting towards customized oral solid dosage forms to meet specific subgroups of patients, including pediatrics and geriatrics. This fuels demand for superdisintegrants with tunable performance profiles enabling faster disintegration or sustained action as needed. The release profile is now differentiated in clinical pipelines by personalization.
• Rise of Biodegradable and Eco Certified Excipients
  Sustainability certifications and biodegradability labeling are becoming influential in procurement decisions for pharmaceutical excipients. There is increased acceptance of disintegrants that are environmentally friendly among formulation teams globally. The trend is in line with the larger-scale pharmaceutical commitment to green chemistry and circular supply chains in the coming years.
• Localized Manufacturing and Regional Specification Alignment
  The manufacture of pharmaceuticals is increasingly regionalized in order to achieve the country-specific regulatory demands and minimize supply chain risk. Local manufacturing centers are now defining local geographic preferred excipient grades that are consistent with local quality and disintegration demands. These factors drive diversified superdisintegrant portfolios tailored by geography and formulation need.

Superdisintegrants MarketGrowth Factors

• Rising Demand for Fast-Dissolving Tablets: Growing preference for patient-friendly dosage forms is propelling the adoption of efficient superdisintegrants.
• Expansion of Generic Drug Manufacturing: Boosting generic drug production worldwide fuels higher consumption of high-performance superdisintegrants.
• Advancements in Natural Excipient Alternatives: Growing focus on natural and biodegradable disintegrants is propelling sustainable formulation practices.
• Collaborative Industry Partnerships and Licensing: Strategic collaborations between excipient manufacturers and pharmaceutical companies are propelling innovation and faster market access.

Market Scope

Strategic Expansion, Innovation, and Global Supply Strengthening the Superdisintegrants Market

• In 2025, BASF SE retained its position as one of the largest exporters of crospovidone and croscarmellose sodium globally, leveraging its established polymer chemistry infrastructure across Europe, Asia, and North America to support formulation partners in over 50 countries.
  JRS Pharma entered the Indian manufacturing landscape in July 2024 by signing an agreement to build a dedicated cotton-based croscarmellose sodium production facility in Mehsana, aimed at reducing imports and supporting local pharmaceutical OEMs with domestically produced superdisintegrants.
• During 2025, Roquette showcased expanded formulation capabilities at AAPS 2025 PharmSci 360, highlighting advanced solutions relevant to superdisintegrants and other excipient innovations, underlining its role as a major global player in pharma excipient technology.
• In 2024–2025, pharma excipient R&D and production facility enhancements were reported at major global events such as CPhI 2025 Frankfurt, where leading producers demonstrated expanded portfolios and technical expertise, indicating ongoing investment in formulation and production capabilities.
• In April 2025 IFF Pharma Solutions showcased next-generation excipient innovations, including technology critical to orally disintegrating tablets that rely on superdisintegrants, at CPHI Japan 2025, reflecting ongoing investment in formulation and production capabilities
• In 2024, the European Union's exports of medicinal and pharmaceutical products grew by 13.5% on year, reaching a total value of €313.4 billion, a record high, underscoring Europe's role as a major production and export source for pharmaceuticals and related formulation ingredients.

Segmental Insights

Product Insights

Why Did the Crospovidone Segment Dominate the Superdisintegrants Market?

The crospovidone segment held the largest revenue share of the market in 2025, due to its ability to provide rapid water wicking and mechanical tablet disintegration. This improves dissolution without the formation of a viscous gel layer, which is an important consideration in immediate-release products. Regulatory frameworks of the FDA SUPAC IR guidance focus on the definition of excipient roles in the change of formulation and promotion of the use of the same performers, like crospovidone.

Crospovidone also has a predictable performance in direct compression, as well as wet and dry granulation methods, enabling pharmaceutical innovators fewer reformulations and quicker scale-up. Furthermore, the crosprovidones' consistent action with poorly water-soluble APIs further boosts segment growth.

The ion exchange resin segment is expected to grow at the fastest CAGR in the coming years, owing to its multifunctional role in tablet formulations, including use as disintegrants, taste masking agents, and controlled release facilitators in oral dosage forms. These synthetic polymers are claimed to have high ionic exchange and structural stability.

They are being used to enhance drug liberation and tablet breakup in orodispersible and other oral dosage forms. Furthermore, researchers have also noted that ion exchange resins can convert drugs into more soluble forms via drug resin complexes, which enhances dissolution profiles in certain oral formulations, further supporting their growth potential.

Form Insights

How the Tablets and Capsules Segment Dominated the Superdisintegrants Market?

The tablets and capsules segment accounted for the highest revenue share of the market in 2025, due to their established role in immediate-release and controlled-release oral therapy regimens widely prescribed across global healthcare systems.

These dosage forms frequently incorporate superdisintegrants to ensure consistent disintegration and rapid drug availability in conventional and generics portfolios. Moreover, the use of tablets and capsules orally in chronic and acute therapeutic settings is expected to facilitate the adoption of tested and proven dosages of tablets and capsules in the coming years.

The mouth-dissolving films (MDFs) segment is expected to grow with the highest CAGR in the market during the studied years, owing to the increasing patient preference for convenient and swallow-friendly dosage forms, particularly among elderly and pediatric populations with swallowing impairments. The development of hot melt extrusion and solvent casting processes helps produce MDFs with high efficiency in terms of uniform thickness and the ability to disperse.
New combinations of excipients enabling flexible loading of active moieties into film matrices were the focus of industry conferences and symposia. Furthermore, the growing demand for patient-centric therapies and expanded R&D focus on sensory acceptable, quick action formats, potentiating the demand for MDFs.

Regional Insights

Why North America Dominated the Superdisintegrants Market?

North America led the market in 2025, as it has the most developed pharma manufacturing systems and a long-term focus on the development of high-quality solid oral dosage, owing to the elaborate quality standards enforced by the U.S. FDA and pharmacy standards in accordance with the USP quality standards. The formulators focus on consistent excipient performance of tablets and capsules.

The FDA launched initiatives in 2025 to boost domestic drug production, including a pilot program and the FDA PreCheck scheme to expedite review and construction of manufacturing facilities, strengthening local production capabilities and encouraging investments in formulation science. Moreover, the leadership in regulatory compliance and advanced formulation practices continues to secure North America's position as a core regional base for excipient utilization.

U.S. – Leading North America's Pharmaceutical Strength

The U.S. leads the market in North America due to its advanced regulatory ecosystem and significant drug production scope. In 2026, regional programs such as the FDA PreCheck and the EO 14293 on onshoring pharmaceuticals support the growth of local production and supply chain resiliency. This makes it easier to integrate technologies in excipient tablet production. Furthermore, continued investments in research and development infrastructure and formulation science have ensured that U.S. drug manufacturers remain in the lead to create complex oral solid dosage forms.

Why is Asia-Pacific Projected to Grow Fastest in the Superdisintegrants Market?

Asia-Pacific is expected to witness the fastest growth during the predicted timeframe, owing to the expanding pharmaceutical production capacity, regulatory improvements, and increasing integration into global supply chains across China, India, South Korea, and Southeast Asia. In 2025, the National Medical Products Administration (NMPA) of China introduced specific GMP annexes of pharmaceutical excipients and packaging materials.

This improves quality control and aligns the local needs with the global practice, which is expected to further raise the level of excipient manufacturing. Oxford Economics projects continued percentage gains in overall production, which supports broader formulation and excipient demand. Additionally, government incentives and policies that support pharmaceutical exports and quality improvements are likely to fuel the market in this region.

India – Driving Growth in Asia Pacific's Pharmaceutical Landscape

China is leading the charge in the Asia-Pacific market, supported by expansive generic drug manufacturing and deep global integration. Pharma exports in India increased to USD 30.5 billion in FY25 as a result of the increasing international demand. This further supports other related excipient segments applied in solid formulations. Furthermore, India's strategic position in the global pharmaceutical value chain is projected to sustain strong momentum for oral dosage technologies and underpin regional growth.

Superdisintegrants Market Value Chain Analysis

• Raw Material Sourcing
  Procurement of cellulose, starches, and polymer precursors forms the foundation of superdisintegrant production.
  Key Players: Wood pulp suppliers, cellulose producers, starch manufacturers
• Chemical Synthesis & Intermediate Production
  Raw materials are chemically modified to produce intermediates with excipient functionality.
  Key Players: Polymer chemical manufacturers, excipient intermediates processors
• Superdisintegrant Manufacturing
  Intermediates are processed into finished superdisintegrants with controlled particle size and purity.
  Key Players: BASF SE, Ashland Global Holdings Inc., DuPont de Nemours Inc., DFE Pharma GmbH & Co. KG
• Distribution & Supply Chain Logistics
  Finished excipients are distributed globally to pharmaceutical manufacturers under GMP/GDP standards.
  Key Players: Global excipient distributors, specialty chemical logistics firms
• Pharmaceutical Formulation & End Use
  Pharmaceutical companies incorporate superdisintegrants into tablets and capsules to enhance disintegration.
  Key Players: Global pharmaceutical manufacturers, CROs/CMOs

Superdisintegrants Market Companies

• Asahi Kasei Corporation
• Ashland
• BASF SE
• Corel Pharma Chem.
• DFE Pharma
• DuPont.
• JRS PHARMA
• Merck KGaA
• NIPPON SODA CO., LTD.
• Roquette Frères.

Recent Developments in the Superdisintegrants Market

• In February 2026, DFE Pharma introduced its Continuous Manufacturing (CM) platform to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes. Developed in collaboration with Gericke, the platform combines CM-ready excipients, an evaluation environment, and multidisciplinary expertise, enabling data-driven decisions from early development through long-term CM operations.(Source: https://www.expresspharma.in)
• In February 2026, Lupin Limited signed a licensing and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada. Utilizing Spektus's proprietary Flexitab oral drug-delivery platform, the partnership combines Lupin's strong Canadian commercial footprint with Spektus's expertise in differentiated formulations.(Source: https://www.lupin.com)
• In October 2025, Asahi Kasei announced the launch of two new specialty grades in its Sonanos excipient portfolio. These next-generation excipients, designed to improve injectable drug formulations, are manufactured under GMP standards, with commercial availability expected in 2027. (Source: https://www.contractpharma.com)
• In September 2025, Eli Lilly and Company announced plans to construct a USD 6.5 billion next-generation manufacturing facility at Generation Park in Houston, Texas. This facility, the second of four new U.S. sites planned for 2025, will focus on producing small-molecule APIs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience.(Source:https://www.prnewswire.com)

Segments Covered in the Report

By Product

• Croscarmellose sodium
• Crospovidone
• Ion Exchange Resin
• Sodium Starch Glycolate
• Others

By Form

• Tablets and Capsules
• Mouth-dissolving Films

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa